{"filings":[{"id":96443,"accession_number":"0001213900-26-050951","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest","event_type":"debt","confidence":"high","bullets":["Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.","Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.","Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.","Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96442,"accession_number":"0001213900-26-043519","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CERo Therapeutics issues $437,500 convertible note to Keystone Capital Partners, 10% interest, due 2027","event_type":"debt","confidence":"high","bullets":["Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.","Note bears interest at 10% per annum, matures April 9, 2027, with up to $1,000,000 total borrowing capacity.","Conversion price is lesser of $0.05 or 80% of avg of 5 lowest intraday prices in 20 days prior to conversion.","Beneficial ownership limitation of 4.99% applies; issuance exempt from registration under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110332,"accession_number":"0001213900-26-025817","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05","event_type":"debt","confidence":"high","bullets":["Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.","Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.","Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.","Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.","Maximum aggregate borrowing up to $1,000,000 under the note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110331,"accession_number":"0001213900-26-016474","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","2.03","3.02","4.01","5.02","9.01"],"status":"ready","headline":"CERo Therapeutics issues $937.5k convertible note, dismisses auditor Wolf & Co., appoints Eric Francois to board","event_type":"other_material","confidence":"high","bullets":["Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.","Dismissed Wolf & Company, P.C. as auditor effective Feb 13, 2026; no disagreements, but prior material weakness in internal controls noted.","Appointed Salberg & Company, P.A. as new auditor effective Feb 13, 2026.","Appointed Eric Francois to board, increasing size to 7; he served as Managing Director at Raymond James, CFO at Scynexis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110330,"accession_number":"0001213900-26-011844","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CER-1236 first-in-human data show no CRS/ICANS; platelet transfusion independence in index AML patient","event_type":"other_material","confidence":"high","bullets":["No cytokine release syndrome (CRS) or ICANS observed despite CD28 costimulatory domain and measurable cell expansion.","Index patient with inv(3) AML achieved platelet transfusion independence for 72 days after multiple CER-1236 doses.","CER-1236 successfully manufactured for all four enrolled patients; study expanded to include MDS and myelofibrosis.","TIM-4 ligand target expressed on AML but not healthy bone marrow; no off-tumor cytotoxicity in preclinical safety assays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110329,"accession_number":"0001213900-26-011587","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Listing Council affirms delisting of CERo Therapeutics securities","event_type":"regulatory","confidence":"high","bullets":["On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.","Delisting and trading suspension originally effective Oct 31, 2025; the Council's affirmance makes the delisting final.","Common stock ticker CERO and warrants ticker CEROW will no longer trade on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110328,"accession_number":"0001213900-26-002187","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CERo Therapeutics Phase 1 CER-1236 trial shows safety, 61-day transfusion-free interval; expands to MDS/MF","event_type":"other_material","confidence":"high","bullets":["First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.","Second patient (MDS/AML) had 61-day platelet transfusion-free interval after CER-1236 treatment.","FDA amendment filed to include advanced MDS and myelofibrosis as additional cohorts.","Company to host analyst call on Jan 7, 2026 at 5:00 PM ET to discuss progress and strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126931,"accession_number":"0001213900-25-123912","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CERO stockholders approve reverse stock split (1:40–1:150) and 32M share increase to equity plan","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set by board at not less than 1:40 or more than 1:150; approved with 8,012,563 for, 2,287,082 against.","Issuance of common shares upon conversion of Series E preferred (Oct 2025 PIPE) approved; 3,304,540 for, 1,422,195 against.","Equity incentive plan share reserve increased by 32,000,000 shares to 32,123,494 total; approved with 2,568,408 for.","Quorum was 10,988,347 shares (52.82% of 20,802,671 outstanding) at the Dec 19, 2025 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126930,"accession_number":"0001213900-25-116971","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital","event_type":"other_material","confidence":"high","bullets":["Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.","Prior agreements (Feb 2024, Nov 2024, July 2025) raised ~$10.4M total: ~$4.4M (Feb), ~$3.1M (Nov), ~$2.9M (July).","Minimum stock price for purchases set at $0.02; single fixed purchase limited to 10,000 shares or $100,000.","Investor's beneficial ownership capped at 4.99% of outstanding shares; registration rights granted.","Agreement is a continuation of the existing equity line program; no additional commitment shares required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126929,"accession_number":"0001213900-25-103661","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31","event_type":"regulatory","confidence":"high","bullets":["Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.","Company has appealed to Nasdaq Listing and Hearing Review Council; also seeks OTC Markets trading.","$4.75M Series E Preferred financing contingent on Nasdaq listing; funding now uncertain.","Early clinical data for CER-1236 in three AML patients shows rapid cell expansion and no toxicity.","Company reviewing cash resources and financing alternatives; no assurance of funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126928,"accession_number":"0001213900-25-099560","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"CERo Therapeutics closes $2.25M initial closing of Series E preferred stock financing, total $7M","event_type":"other_material","confidence":"high","bullets":["Initial closing of 3,816 Series E preferred shares raised $2.25M gross proceeds on Oct 16, 2025.","Amendment to SPA added an additional buyer and increased initial closing by $500k; total remains $7M.","Series E preferred stock terms filed as Certificate of Designations on Oct 14, 2025.","Remaining $4.75M to be funded at additional closings under the Securities Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126927,"accession_number":"0001213900-25-098421","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CERo Therapeutics raises up to $7M via Series E convertible preferred private placement","event_type":"other_material","confidence":"high","bullets":["Initial closing of ~$1.8M; Series E convertible at $1,000 stated value, conversion price $4.1625 per share.","Series C and D conversion price reduced to $1.76 as consent for pari passu treatment with Series E.","Company to seek stockholder approval by Oct 31, 2025 for lower conversion; meeting target Dec 31, 2025.","Bankruptcy trigger and company optional redemption each at 25% premium.","Registration rights agreement filed to register resale of conversion shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143722,"accession_number":"0001213900-25-090107","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CERO Therapeutics updates investor presentation with no material new disclosures","event_type":"other","confidence":"low","bullets":["Company furnished updated corporate presentation dated September 2025 as Exhibit 99.1, intended for investor meetings.","No financial results, clinical updates, or guidance were included in the filing or the attached exhibit text.","Presentation available on company website but substantive content not extracted from the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143721,"accession_number":"0001213900-25-084737","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CERo Therapeutics receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for CER-1236 in AML, adding to existing Orphan Drug Designation.","Benefits include increased FDA interactions, potential priority review, rolling submission, and expanded access.","Phase 1/1b study underway evaluating CER-1236 in relapsed/refractory AML, MRD-positive, or TP53-mutated MDS/AML.","CEO Chris Ehrlich noted the designation validates program urgency and may accelerate development and market timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143720,"accession_number":"0001213900-25-084498","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.","Trading suspension and delisting scheduled for September 8, 2025, unless hearing stays action.","Company requested hearing on September 3, 2025, to appeal determination and present compliance plan.","Plan may include public or private financing to increase equity; no assurance of success.","Company subject to mandatory hearings panel monitor until May 7, 2026, after prior non-compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143719,"accession_number":"0001213900-25-065655","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"CERO Therapeutics closes additional $397,600 private placement of Series D Preferred Stock","event_type":"other_material","confidence":"high","bullets":["Issued 497 shares of Series D convertible preferred stock for gross proceeds of approximately $397,600.","Sale conducted as an Additional Closing under previously announced Securities Purchase Agreement dated April 21, 2025.","Exempt from registration under Section 4(a)(2) and Rule 506 of the Securities Act.","Shares are convertible into common stock; terms set forth in Certificate of Designations filed April 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143718,"accession_number":"0001213900-25-063475","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital","event_type":"other_material","confidence":"high","bullets":["New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.","Fixed purchases per notice capped at lower of 10,000 shares or $100,000; VWAP purchases aggregate limit of $10M.","Beneficial ownership limitation of 4.99% per purchase.","Registration Rights Agreement filed concurrently for shares issued.","Replaces prior equity lines from Feb '24 and Nov '24 which had raised ~$7.5M combined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143717,"accession_number":"0001213900-25-061911","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CERo Therapeutics regains Nasdaq bid price compliance; delisting hearing canceled","event_type":"regulatory","confidence":"high","bullets":["On July 7, 2025, Nasdaq determined CERo regained compliance with the $1.00 minimum bid price rule.","Company had received a deficiency notice on June 11, 2025, for 30 consecutive days of sub-$1.00 closing bid.","CERo timely appealed the delisting determination and requested a hearing, which stayed the suspension.","Nasdaq canceled the scheduled hearing because compliance was restored; common stock continues on Nasdaq Capital Market.","Tickers CERO (common) and CEROW (warrants) remain listed on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161949,"accession_number":"0001213900-25-059738","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CERo Therapeutics raises $1.85M via Series D preferred stock; adds new institutional investors","event_type":"other_material","confidence":"high","bullets":["Closed additional closing of 2,315 shares of Series D convertible preferred stock for gross proceeds of ~$1,852,000.","Entered into Amendment No. 1 to the Securities Purchase Agreement adding new institutional investors as buyers.","New investors join through joinder agreements, becoming parties to the existing Securities Purchase Agreement.","The Series D preferred stock is convertible into shares of CERO common stock; offering exempt under Rule 506/Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161948,"accession_number":"0001213900-25-054961","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Orphan Drug Designation to CERo's CER-1236 for AML treatment","event_type":"regulatory","confidence":"high","bullets":["FDA Orphan Drug Designation granted to CER-1236 for acute myeloid leukemia (AML).","CER-1236 is an engineered T cell therapy leveraging phagocytic mechanisms; currently in Phase 1 trial.","ODD qualifies CERo for 7-year marketing exclusivity, FDA trial assistance, and fee exemptions.","AML is a life-threatening condition affecting ≤200,000 US patients annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161947,"accession_number":"0001213900-25-054371","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).","Not eligible for standard compliance period due to prior reverse stock splits; plans to request a hearing.","Effected 1-for-20 reverse stock split on June 13, 2025; closing bid price was $7.31.","No assurance that bid price will remain above $1.00 or that hearing will grant continued listing.","Common stock (CERO) and warrants (CEROW) continue trading on Nasdaq pending hearing outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161946,"accession_number":"0001213900-25-053292","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"CERo Therapeutics announces 1-for-20 reverse stock split effective June 13, 2025","event_type":"other_material","confidence":"high","bullets":["Outstanding shares reduced from ~10,321,839 to ~516,092; par value $0.0001 unchanged.","Split-adjusted trading begins June 13 under symbol CERO; new CUSIP 71902K402.","No fractional shares; fractional holders receive rounding up to next whole share.","Proportional adjustments made to outstanding options, warrants, and preferred stock.","Stockholders approved a 1-for-2 to 1-for-25 range at May 29, 2025 annual meeting; board set 1-for-20."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161945,"accession_number":"0001213900-25-051750","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way","event_type":"other_material","confidence":"high","bullets":["Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.","Series D convertible preferred converts to common; additional $2.25M possible at investors' option.","Proceeds to support clinical development of CAR-T candidate CER-1236, including IND allowances and site activation at MDACC.","Company reports first-in-human dosing in AML for CER-1236, a TIM-4L-targeted autologous CAR-T.","CEO Chris Ehrlich cites continued investor support and clinical progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161944,"accession_number":"0001213900-25-050055","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025","event_type":"leadership","confidence":"high","bullets":["CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.","CFO Andrew Kucharchuk receives base salary of $300,000/year and a one-time performance bonus of 30% of base salary.","Ehrlich receives equity awards including an option for 238,971 shares (granted March 4, 2025) and a second option for 185,529 shares.","Kucharchuk receives an option for 152,500 shares, subject to board approval, vesting over time and performance milestones.","The new agreements replace prior consulting agreements and convert both roles to full-time employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161943,"accession_number":"0001213900-25-048998","cik":1870404,"company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CERO","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.","Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000 shares.","Election of Class I directors Michael Byrnes and Lindsey Rolfe, M.D. to serve until 2028 annual meeting.","Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year 2025.","Also approved issuance of shares upon exercise of February 2025 warrants and conversion of Series D preferred below market price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}